DIRS.INFO The most relevant business & tech news

☆ Morgan Stanley sees Eli Lilly shares rallying on data showing heart benefit of Novo's obesity drug
▼ + stars: | 2023-08-08 | by ( Yun Li | ) www.cnbc.com time to read: +1 min

Danish drugmaker Novo Nordisk 's promising data on its obesity drug Wegovy should benefit Eli Lilly 's pipeline and its stock, according to Morgan Stanley. Shares of Novo Nordisk soared 15% in early trading Tuesday after late-stage trial data showed that Wegovy reduced the risk of major cardiovascular events, such as heart attacks or strokes, by 20%, compared with a placebo. "This is above our expectations and our prior analysis," Morgan Stanley analyst Terence Flynn said. Flynn has an overweight rating on Eli Lilly and a $560 12-month price target, which would translate into a 23% gain from Monday's close of $454.08. Eli Lilly raised its full-year guidance Tuesday as second-quarter profit jumped 85% from the same period a year ago on strong sales resulting from its drug pipeline.

Persons: Eli Lilly, Morgan Stanley, Terence Flynn, Eli Lilly's, Flynn, — CNBC's Michael Bloom Organizations: Nordisk, Novo Nordisk Locations: Indianapolis

☆ Here are Friday's biggest analyst calls: SoFi Technologies, AutoZone, Nvidia, Meta and more
▼ + stars: | 2023-06-16 | by ( Sarah Min | ) www.cnbc.com time to read: +6 min

Bank of America downgrades SoFi Technologies to neutral from buy The downgrade follows SoFi' s recent rally. Our C$51 Price Target is 39% above the current stock price and we see close to 3:1 upside/downside skew." UBS upgrades AutoZone to buy from neutral Analyst Michael Lasser raised the price target to $2,900 from $2,800. Wells Fargo initiates Neogen Corporation at overweight and $22 price target Wells Fargo said it liked the company's improving margins. Wells Fargo initiates Bio-Rad Laboratories Inc. at overweight and $550 price target Wells said Bio-Rad's valuation is attractive at current levels.

Persons: Jefferies, John Hecht, LendingClub, Morgan Stanley, Mauricio Serna, Aritzia, Michael Lasser, Carvana, it's, Wells, Ph3, Wells Fargo, Piper Sandler, TD Cowen downgrades, LOE, Michael Bloom Organizations: . Bank of America, Technologies, Nvidia, Bank of America, UBS, West Pharmaceutical Services, Stevanato, MorphoSys, Neogen, Rad Laboratories Inc, SoFi Technologies, Health Companies Locations: EBITDA, 4Q23, BLCO

☆ Playing defense as market tumbles — 10 stocks that outperform in recessions
▼ + stars: | 2023-03-16 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

As the market tumbles and recession risks rise, it's time to start playing defense and buying stocks that are poised to outperform in the later innings of the U.S. market cycle, according to Wolfe Research. Bond yields have fallen, oil prices have steeply dropped and stock market volatility has surged. With that in mind, here are 10 of the stocks that Wolfe Research believes outperform the rest of the market during a recession. It has an estimated 2023 P/E of 24.7x and an EV/2023 estimated EBITDA of 16.4x. The drugmaker has an estimated 2023 P/E of 37.2x and an EV/2023 estimated EBITDA of 28.7x.

☆ Here are Thursday's biggest analyst calls: Credit Suisse, Amazon, Block, First Republic, FedEx & more
▼ + stars: | 2023-03-16 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Thursday's biggest calls on Wall Street: JPMorgan reiterates Amazon as overweight JPMorgan said growth deceleration concerns are overdone. Stifel upgrades FedEx to buy from hold Stifel said FedEx shares are compelling at current levels. JPMorgan reiterates Credit Suisse as overweight JPMorgan said it's standing by shares of the banking giant. JPMorgan upgrades Motorola Solutions to overweight from neutral JPMorgan called the telecom equipment company "high quality." Bank of America upgrades Takeda Pharmaceuticals to buy from neutral Bank of America said called Takeda a "stable value stock."

☆ Here are Friday's biggest analyst calls: Apple, Tesla, Alphabet, Kroger, Meta, Silvergate, UPS & more
▼ + stars: | 2023-03-03 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Friday's biggest calls on Wall Street: Morgan Stanley reiterates Apple as a top pick Morgan Stanley said it sees a "catalyst rich event path" for the tech giant. Morgan Stanley names Alphabet, Amazon and Meta top AI picks Morgan Stanley named Alphabet, Amazon and Alphabet as top picks and said AI is at an inflection point. Barclays reiterates Alphabet as overweight Barclays said it's standing by its overweight rating on the stock but sees it range-bound for the foreseeable future. Morgan Stanley reiterates Eaton as a top pick Morgan Stanley said it sees several cyclical growth drivers for the multination power management company. Morgan Stanley names Eli Lilly as a catalyst driven idea Morgan Stanley named Eli Lilly as a catalyst driven idea, saying that the stock "levered" to a likely positive outcome from upcoming obesity drug trials.

☆ Here are Friday's biggest analyst calls of the day: Apple, Amazon, Uber, Nike, Boeing, Netflix & more
▼ + stars: | 2023-01-06 | by ( Michael Bloom | ) www.cnbc.com time to read: +10 min

Baird names Boeing a top 2023 pick Baird named Boeing as a top idea this year and says it sees a recovery in aerospace. UBS names Target a top pick in 2023 UBS says it sees Target as a market share gainer in 2023. Wells Fargo initiates Snowflake as overweight Wells said in its initiation of the stock that it's built to "weather the storm." Piper Sandler names Amazon a top 2023 pick Piper Sandler says it sees share gains and easing comps for the e-commerce giant. " Bank of America names Domino's a top 2023 pick The firm says Domino's is well positioned in a declining macroeconomic environment.

☆ Goldman Sachs says this biotech stock can double on treatment against childhood brain tumor
▼ + stars: | 2022-12-05 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Investors looking for exposure to the biotechnology sector should consider buying Day One Biopharmaceuticals , a stock that can more than double from current levels, according to Goldman Sachs. Analyst Andrea Tan initiated coverage on the biotechnology stock with a buy rating, saying positive data in the first quarter on a possible treatment for childhood brain tumors could unlock a multibillion-dollar sales opportunity. Initial reads on tovorafenib, a treatment for pediatric low-grade glioma, have so far been promising, according to the note. Tovorafenib is under evaluation in a clinical trial called FIREFLY-1 for relapsed pLGG, with data expected in the first quarter of 2023. The analyst expects positive topline data from the trial could serve as a catalyst for the stock and "support a path to approval" for the therapy.

☆ Goldman Sachs says this little-known biotech stock can double on potentially ‘blockbuster’ revenue
▼ + stars: | 2022-12-01 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Investors should buy biopharma stock Altimmune as it can double from here depending on the success of a new obesity drug, according to Goldman Sachs. However, the analyst expects that the growing obesity market is not a "zero-sum game" and has niches for new players. "We believe that cardiovascular and lipid benefits conferred by pemvidutide will allow ALT to earn meaningful market share and blockbuster revenues," Jenkins wrote. The analyst expects further studies on the pemvidutide's treatment on other diseases could also help differentiate the drug. Shares of Altimmune are up 8% this year, but the analyst expects they'll advance further.

☆ Goldman upgrades Biogen, says it’s poised to address early Alzheimer’s market next year
▼ + stars: | 2022-10-26 | by ( Tanaya Macheel | ) www.cnbc.com time to read: +2 min

Biogen shares have a lot more potential upside for investors thanks to positive new data around the company's early Alzheimer's drug, Goldman Sachs said Wednesday. The upgrade followed the company's earnings call, which had a big focus on the drug, lecanemab, an anti-amyloid antibody that is in phase 3 trials. Goldman also raised its revenue estimates for the drug to $14 billion in 2035, compared with prior estimates of $2 billion. "The company is now poised to address the early Alzheimer's disease market in 2023+ following the recent topline lecanemab Ph3 (CLARITY-AD) data," Goldman analyst Salveen Richter said in a note. "With BIIB shares now trading at ~$270 post the topline CLARITY-AD data, there is roughly ~$80/share reflected in the stock for Alzhiemer's disease," Richter said.

Search resuls for: "Ph3"

9 mentions found